Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort

Abstract

// Yao Zhu 1, 2, * , Cheng-Tao Han 1, 2, * , Hai-Tao Chen 3, 4, 5 , Fang Liu 3, 4, 5 , Gui-Ming Zhang 1, 2 , Wei-Yi Yang 1, 2 , Jian-Feng Xu 3, 4, 5, 6 , Ding-Wei Ye 1, 2 1 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China 2 Department of Oncology, Shanghai Medical Colleague, Fudan University, Shanghai, China 3 Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China 4 State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China 5 Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China 6 Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA * These authors have contributed equally to this work Correspondence to: Ding-Wei Ye, e-mail: yedingwei1963@126.com Keywords: prostate cancer, age, genetic score, predictive performance, multivariate model Received: February 06, 2015      Accepted: May 07, 2015      Published: May 15, 2015 ABSTRACT Background: We investigated whether age influences the predictiveness of genetic risk score (GRS) for prostate cancer (PCa) in a Chinese hospital-based biopsy cohort. Methods: We included consecutive patients who underwent prostate biopsies in two tertiary centers between 2012 and 2014. GRS was calculated using 24 PCa-associated genetic variants and its predictiveness was assessed by area under curve (AUC). Results: Of 1120 men tested, 724 with prostate-specific antigen (PSA) < 20 ng/ml were selected for further analysis. Patients were divided into 3 groups by age cutoffs at 60 and 70 years. GRS significantly predicted PCa for all patients (AUC: 0.561; 95% CI: 0.514–0.609) and was an independent predictor in multivariate analysis for the 60–70 year-olds (AUC: 0.612, 95% CI: 0.541–0.684), but not for patients aged < 60 years or ≥70 years. For PCa with Gleason score ≥7, GRS discriminative ability was 0.582 (95% CI=0.527–0.637) for all patients, and 0.647 (95% CI: 0.541–0.684) for the 60–70 year-old group. Conclusion: GRS significantly increased clinical prediction of PCa and high-grade disease in Chinese men aged 60–70 years, which implies that men in this age group would benefit most from genetic testing.